Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 May 31, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Provides Update on Phase 3 TROPiCS-04 Study May 30, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 May 22, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis May 18, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy May 14, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program May 09, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers ACLX GILD Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 May 07, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences April 30, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV April 26, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces First Quarter 2024 Financial Results April 25, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 April 08, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six March 28, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program March 28, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD XLO Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer March 11, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities March 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 March 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD MRK Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD MRUS New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 March 05, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health March 05, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. February 27, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance February 26, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 February 26, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences February 20, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics February 12, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers CBAY GILD Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC February 09, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend February 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results February 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Ted Love, MD, Joins Gilead Sciences’ Board of Directors February 01, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy January 30, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024 January 23, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
